Analyst Price Target is $1.83
▲ +58.05% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Allakos in the last 3 months. The average price target is $1.83, with a high forecast of $3.00 and a low forecast of $1.00. The average price target represents a 58.05% upside from the last price of $1.16.
Current Consensus is
Hold
The current consensus among 5 investment analysts is to hold stock in Allakos. This Hold consensus rating has held steady for over two years.
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Read More